Refine by
Applications
- Microbiome Therapeutics for Patients and Physicians
- Vaccine for COVID-19
- Freeze-Dried Hemostatic for Patients
- BSD-2000 - Deep Regional Hyperthermia System for Clinical
- Medical cannabis solutions for regulatory pathway sector
- Medical cannabis solutions for mental health costs sector
- IONICON PTR-TOF instruments deployed for COVID-19 detection in breath
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- Microbiota for Restoration Therapy
- Microbiota Based Product for Physician-Sponsored Studies
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Liquid Biopsy Technology for Hereditary Cancer Screening
Clinical Phase Equipment & Supplies
226 equipment items found
Manufactured by:Hemostemix Inc. based inCalgary, ALBERTA (CANADA)
Hemostemix is currently conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial for patients with critical limb ischemia at sites in the Canada and United ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:BCN Peptides S.A. based inSant Quintí de Mediona, SPAIN
BCN Peptides ensures the highest qualities and shortest times thanks to our experience in the manufacturing of peptides for all clinical phases, from pre-clinical to phase I, II, III and commercial stage. Our facility has been specially designed by BCN Peptides applying our expert know-how in Solid Phase Peptide ...
Manufactured by:RapiGEN Inc. based inSuwon-si, SOUTH KOREA
NS1 (non-structural protein 1) is a highly conserved glycoprotein that is essential for the viability of the Dengue virus and is produced both in membrane-associated and secretory forms by the virus. NS1 antigen is present at a high concentration in the blood of dengue virus-infected patients during the early clinical phase of the ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX04-O, recombinant anti-VEGF humanised monoclonal antibody injection. It is indicated for wet age-related macular degeneration (wAMD). HLX04-O was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. In April 2022, the first patient in Australia and Latvia was dosed in the ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. We have achieved the formulation feasibility and cleared the regulatory hurdles associated with ...
Manufactured by:iMouse GmbH based inBerlin, GERMANY
Its intelligent Vision AI and machine learning platform aids scientists in refining the prediction of new drug candidates, enhancing translation from preclinical to clinical phases while minimizing failure ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of protective and ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
With V-306 Virometix offers a differentiated approach to RSV vaccine development. Our vaccine candidate – already in clinical phase I – demonstrates strong, durable, specific and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease ...
Manufactured by:MitoImmune Therapeutics Inc. based inGangnam-gu, SOUTH KOREA
MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of oral mucositis as a side effect of chemoradiation ...
Manufactured by:SiO2 Materials Science based inAuburn, ALASKA (USA)
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
Manufactured by:SiO2 Materials Science based inAuburn, ALASKA (USA)
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
Manufactured by:CanaQuest Medical Corp. based inMississauga, ONTARIO (CANADA)
Clinical testing on humans can only begin after a pre-clinical phase, involving laboratory studies (in vitro) and tests on animals, which has shown that the experimental drug is considered safe and effective. However, no animal is sufficiently similar to humans (even genetically modified ones) to make human testing unnecessary. ...
by:Palvella Therapeutics. based inWayne, PENNSYLVANIA (USA)
QTORIN™ rapamycin 3.9% is a novel targeted topical therapy being studied for Microcystic Lymphatic Malformations (Micro LM). Palvella is enrolling a phase 2 clinical study for people with Micro ...
Manufactured by:Lung Therapeutics, Inc. based inAustin, TEXAS (USA)
A pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia. A loculated pleural effusion (LPE) occurs when scar tissue forms in the pleural cavity, trapping the fluid and preventing drainage. Our lead compound, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue. We believe ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
Manufactured by:PolyActiva Pty Ltd. based inParkville, AUSTRALIA
Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension. Clinical Investigation Stage: Phase ...
Manufactured by:PolyActiva Pty Ltd. based inParkville, AUSTRALIA
Being developed to reduce the risk of Endophthalmitis following ocular (cataract) surgery. Clinical Investigation Stage: Phase ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
We are developing mGlu2 NAM as a novel orally available treatment for mNCD associated with Alzheimer’s disease, Parkinson’s disease and depressive disorders. The program is in clinical candidate selection phase and we expect to enter IND enabling studies early in H2 ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, ...